In a significant development in the realm of weight management, the U.S. Food and Drug Administration (FDA) has granted approval for Foundayo, an oral medication aimed at aiding weight loss, produced by Eli Lilly. This marks Foundayo as the second GLP-1 (glucagon-like peptide-1) medication approved for use in the United States, following the introduction of Novo Nordisk’s Wegovy in December 2025. The approval, which was achieved in a remarkable 50 days after Eli Lilly submitted its application, reflects a commitment to expediting access to new healthcare solutions.
Overview of Foundayo
Foundayo is designed for adults grappling with obesity or those who are overweight and dealing with associated health issues. Eli Lilly has emphasised that the medication should be used in conjunction with a reduced-calorie diet and increased physical activity to maximise its effectiveness. While the drug is intended for adult patients, its safety for children remains uncertain.
The FDA highlighted the swift approval process as a testament to the agency’s efforts to streamline operations and enhance collaboration with pharmaceutical companies. “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritise fast and thorough work from the agency and industry partners,” stated FDA Commissioner Martin Makary.
Efficacy and Dosage Information
Clinical trials for Foundayo revealed promising results, with participants on the highest dosage losing an average of 27.3 pounds (12.3 kilograms) over the course of treatment, compared to a mere 2.2 pounds (0.9 kg) among those receiving a placebo. This significant weight loss underscores the potential efficacy of the medication for those struggling with obesity.
The recommended starting dose of Foundayo is set at 0.8 milligrams, escalating to 2.5 mg after 30 days, and then to 5.5 mg after an additional month. Depending on individual response and tolerability, further increases to dosages of 9 mg, 14.5 mg, or 17.2 mg may be considered after at least 30 days at each level. Eli Lilly has stated that for those without insurance, the monthly cost of Foundayo will be approximately $149.
Side Effects and Safety Concerns
As with any medication, Foundayo is not without its potential side effects. Common adverse reactions reported include nausea, constipation, diarrhoea, vomiting, indigestion, abdominal discomfort, headaches, fatigue, and hair loss. More critically, the medication may pose risks, including the possibility of thyroid tumours, which could lead to thyroid cancer.
Recent studies have raised additional concerns regarding GLP-1 drugs in general. Research from the University of British Columbia in 2023 indicated a potential association between these medications and an increased risk of stomach paralysis, pancreatitis, and bowel obstruction. Additionally, a 2024 study from Harvard suggested a link between GLP-1 medications and sudden, irreversible vision loss.
Implications for Public Health
The introduction of Foundayo into the market provides a new option for individuals struggling with weight loss, especially those facing obesity-related health complications. However, the potential side effects and the need for further research into the long-term implications of such treatments cannot be overlooked.
Why it Matters
The approval of Foundayo signifies a critical step forward in the fight against obesity, a growing public health crisis. While access to effective medications is paramount, it is equally important to approach their use with caution, ensuring that patients are well-informed about the potential risks and side effects. As healthcare advocates, we must continue to monitor the impact of such medications on patient health and advocate for comprehensive support systems that include nutritional guidance and lifestyle changes, thereby addressing the multifaceted nature of obesity.
